Site of effect of LY2951742 for migraine prophylaxis-Authors' reply

David W. Dodick; Peter J. Goadsby; Egilius L.H. Spierings; Joel C. Scherer; Steven P. Sweeney; David S. Grayzel

doi:10.1016/S1474-4422(14)70309-6

Site of effect of LY2951742 for migraine prophylaxis-Authors' reply

David W. Dodick, Peter J. Goadsby, Egilius L.H. Spierings, Joel C. Scherer, Steven P. Sweeney, David S. Grayzel

Neurology

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	32-33
Number of pages	2
Journal	The Lancet Neurology
Volume	14
Issue number	1
DOIs	https://doi.org/10.1016/S1474-4422(14)70309-6
State	Published - Jan 1 2015

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(14)70309-6

Cite this

@article{953805d54512424a9fb88cc90f576cc0,

title = "Site of effect of LY2951742 for migraine prophylaxis-Authors' reply",

author = "Dodick, {David W.} and Goadsby, {Peter J.} and Spierings, {Egilius L.H.} and Scherer, {Joel C.} and Sweeney, {Steven P.} and Grayzel, {David S.}",

note = "Funding Information: DWD has served on advisory boards or consulted for Allergan, Amgen, Alder, Arteaus Therapeutics, Pfizer, Boston Scientific, Medtronic, St Jude, Bristol-Myers Squibb, Lundbeck, Impax, MAP, Electrocore, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies, Ethicon Johnson and Johnson, Zogenix, Supernus, and Labrys; has received funding for travel, speaking, or editorial activities, or royalty payments from IntraMed, SAGE Publishing, Sun Pharma, Allergan, Oxford University Press, American Academy of Neurology, West Virginia University Foundation, Canadian Headache Society, Healthlogix, Wiley, Universal Meeting Management, WebMD, UptoDate, Oregon Health Science Center, Starr Clinical, Decision Resources, and Synergy. PJG is on advisory boards for Allergan, Colucid, MAP pharmaceuticals, MSD, eNeura, Autonomic Technologies, Boston Scientific, Electrocore, Eli Lilly, Medtronic, Linde Gases, Arteaus Therapeutics, AlderBio, and Bristol-Myers Squibb; has consulted for Pfizer, Nevrocorp, Lundbeck, Zogenix, Impax, Zosano, and Dr Reddy's Laboratories; has been compensated for expert legal testimony in a patent matter unrelated to CGRP mechanisms; has received grant support from Allergan, Amgen, MAP, and MSD; and has received honoraria for editorial work from Journal Watch Neurology and for developing educational materials and teaching for the American Headache Society. ELHS has served as a consultant to Arteaus Therapeutics and received a research grant from Arteaus Therapeutics as an investigator in the present study. JCS was an employee of Eli Lilly, but has since retired. SPS is an employee of Arteaus Therapeutics. DSG is an employee of Arteaus Therapeutics and owns stock or stock options in Arteaus.",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/S1474-4422(14)70309-6",

language = "English (US)",

volume = "14",

pages = "32--33",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "1",

}

TY - JOUR

T1 - Site of effect of LY2951742 for migraine prophylaxis-Authors' reply

AU - Dodick, David W.

AU - Goadsby, Peter J.

AU - Spierings, Egilius L.H.

AU - Scherer, Joel C.

AU - Sweeney, Steven P.

AU - Grayzel, David S.

N1 - Funding Information: DWD has served on advisory boards or consulted for Allergan, Amgen, Alder, Arteaus Therapeutics, Pfizer, Boston Scientific, Medtronic, St Jude, Bristol-Myers Squibb, Lundbeck, Impax, MAP, Electrocore, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies, Ethicon Johnson and Johnson, Zogenix, Supernus, and Labrys; has received funding for travel, speaking, or editorial activities, or royalty payments from IntraMed, SAGE Publishing, Sun Pharma, Allergan, Oxford University Press, American Academy of Neurology, West Virginia University Foundation, Canadian Headache Society, Healthlogix, Wiley, Universal Meeting Management, WebMD, UptoDate, Oregon Health Science Center, Starr Clinical, Decision Resources, and Synergy. PJG is on advisory boards for Allergan, Colucid, MAP pharmaceuticals, MSD, eNeura, Autonomic Technologies, Boston Scientific, Electrocore, Eli Lilly, Medtronic, Linde Gases, Arteaus Therapeutics, AlderBio, and Bristol-Myers Squibb; has consulted for Pfizer, Nevrocorp, Lundbeck, Zogenix, Impax, Zosano, and Dr Reddy's Laboratories; has been compensated for expert legal testimony in a patent matter unrelated to CGRP mechanisms; has received grant support from Allergan, Amgen, MAP, and MSD; and has received honoraria for editorial work from Journal Watch Neurology and for developing educational materials and teaching for the American Headache Society. ELHS has served as a consultant to Arteaus Therapeutics and received a research grant from Arteaus Therapeutics as an investigator in the present study. JCS was an employee of Eli Lilly, but has since retired. SPS is an employee of Arteaus Therapeutics. DSG is an employee of Arteaus Therapeutics and owns stock or stock options in Arteaus.

PY - 2015/1/1

Y1 - 2015/1/1

UR - http://www.scopus.com/inward/record.url?scp=84918523813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918523813&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(14)70309-6

DO - 10.1016/S1474-4422(14)70309-6

M3 - Letter

C2 - 25496895

AN - SCOPUS:84918523813

SN - 1474-4422

VL - 14

SP - 32

EP - 33

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 1

ER -

Site of effect of LY2951742 for migraine prophylaxis-Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this